Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Shubham Batra, Prabhjeet Kaur Bamrah & Manjusha Choudhary. (2023) Sodium-glucose transporter (SGLT2) inhibition: A potential target for treatment of type-2 Diabetes Mellitus with Natural and Synthetic compounds. Egyptian Journal of Basic and Applied Sciences 10:1, pages 69-82.
Read now
Read now
Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu, Hisae Imazeki, Hidekazu Ochiai & Soichi Sakai. (2018) Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. Current Medical Research and Opinion 34:6, pages 981-994.
Read now
Read now
Nobuya Inagaki, Shin-ichi Harashima & Hiroaki Iijima. (2018) Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients. Expert Opinion on Pharmacotherapy 19:8, pages 895-908.
Read now
Read now
Daisuke Yabe, Yoshiyuki Hamamoto, Yusuke Seino, Hitoshi Kuwata, Takeshi Kurose & Yutaka Seino. (2017) Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 16:10, pages 1211-1218.
Read now
Read now
Yukihiro Chino, Masatoshi Hasegawa, Yoshiki Fukasawa, Yoko Mano, Kagumi Bando, Atsunori Miyata, Yasuhiro Nakai, Hiromi Endo & Jun-ichi Yamaguchi. (2017) In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor. Xenobiotica 47:4, pages 314-323.
Read now
Read now
Atsunori Miyata, Masatoshi Hasegawa, Kenji Hachiuma, Haruyuki Mori, Nobuko Horiuchi, Akiko Mizuno-Yasuhira, Yukihiro Chino, Shigeji Jingu, Soichi Sakai, Yoshishige Samukawa, Yasuhiro Nakai & Jun-ichi Yamaguchi. (2017) Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium–glucose cotransporter 2 inhibitor, in humans. Xenobiotica 47:4, pages 332-345.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2017) Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 13:2, pages 211-223.
Read now
Read now
K. Pafili, E. Maltezos & N. Papanas. (2016) The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes. Expert Opinion on Investigational Drugs 25:10, pages 1133-1152.
Read now
Read now
Masatoshi Hasegawa, Yukihiro Chino, Nobuko Horiuchi, Kenji Hachiuma, Masahiro Ishida, Yoshiki Fukasawa, Yasuhiro Nakai & Jun-ichi Yamaguchi. (2015) Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent. Xenobiotica 45:12, pages 1105-1115.
Read now
Read now
Molly G. Minze, Robin L. Koffarnus, Trista A. Bailey, Sandy Diec & Krystal L. Edwards. (2015) Sodium-glucose co-transporter 2 inhibitors: evidence and place in therapy. Expert Review of Endocrinology & Metabolism 10:6, pages 645-661.
Read now
Read now
Kalliopi Pafili & Nikolaos Papanas. (2015) Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?. Expert Opinion on Pharmacotherapy 16:4, pages 453-456.
Read now
Read now
Articles from other publishers (12)
Iryna Kostitska, Nadia Protas & Liliia Petrovska. (2023) Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD). Diabetes Obesity Metabolic Syndrome:5, pages 8-37.
Crossref
Crossref
Marina Shestakova, Boris Kvasnikov, Ekaterina Erina, Elena Isachenko & Alexander Andreev. (2023) Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial. BMJ Open Diabetes Research & Care 11:3, pages e003290.
Crossref
Crossref
Deep Dutta, Jyoti Kadian, Kunal Mahajan, Anil Dhall & Meha Sharma. (2023) Efficacy and safety of luseogliflozin in improving glycaemic and non-glycaemic outcomes in type-2 diabetes: A meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 17:3, pages 102742.
Crossref
Crossref
Zhongjian Wang, Guopeng Wang & Jiawei Ren. (2022) Using a Mathematical Modeling To Simulate Pharmacokinetics and Urinary Glucose Excretion of Luseogliflozin and Explore the Role of SGLT1/2 in Renal Glucose Reabsorption. ACS Omega 7:51, pages 48427-48437.
Crossref
Crossref
Jonali Ramani, Harshil Shah, Vivek K. Vyas & Manmohan Sharma. (2022) A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present. European Journal of Medicinal Chemistry Reports 6, pages 100074.
Crossref
Crossref
Gendai Lee. (2022) Luseogliflozin Additively Enhances the Glucose-Lowering Effect of an Incretin Modulator in a High-Carbohydrate Diet. Cureus.
Crossref
Crossref
Li Di, Amanda Balesano, Samantha Jordan & Sophia M. Shi. (2021) The Role of Alcohol Dehydrogenase in Drug Metabolism: Beyond Ethanol Oxidation. The AAPS Journal 23:1.
Crossref
Crossref
Kashif Haider, Ankita Pathak, Ankit Rohilla, Md Rafi Haider, Kamal Ahmad & M. Shahar Yar. (2019) Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review. European Journal of Medicinal Chemistry 184, pages 111773.
Crossref
Crossref
Jaime Davidson, Sanjay Kalra, Vikram Singh, Mayuresh Fegade, Gursimran Singh & Amey Mane. (2017) Resolving the KgA1c paradox in the management of type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11, pages S159-S168.
Crossref
Crossref
R. Nishimura, H. Omiya, K. Sugio, M. Ubukata, S. Sakai & Y. Samukawa. (2016) Sodium‐glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low‐carbohydrate diet. Diabetes, Obesity and Metabolism 18:7, pages 702-706.
Crossref
Crossref
Yunoshin Tamura, Hiroh Miyagawa, Tatsusada Yoshida & Hiroshi Chuman. (2015) Binding interaction of SGLT with sugar and thiosugar by the molecular dynamics simulation. Biochimica et Biophysica Acta (BBA) - Biomembranes 1848:11, pages 2799-2804.
Crossref
Crossref
Tomohide Hayami, Yoshiro Kato, Hideki Kamiya, Masaki Kondo, Ena Naito, Yukako Sugiura, Chika Kojima, Sami Sato, Yuichiro Yamada, Rina Kasagi, Toshihito Ando, Saeko Noda, Hiromi Nakai, Eriko Takada, Emi Asano, Mikio Motegi, Atsuko Watarai, Koichi Kato & Jiro Nakamura. (2015) Case of ketoacidosis by a sodium‐glucose cotransporter 2 inhibitor in a diabetic patient with a low‐carbohydrate diet. Journal of Diabetes Investigation 6:5, pages 587-590.
Crossref
Crossref